Mallika P Patel1, Eric S Lipp2, Elizabeth S Miller2, Patrick N Healy3, James E Herndon3, Katherine B Peters2. 1. Department of Pharmacy, Duke University Medical Center, Durham, North Carolina, USA. 2. Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA. 3. Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA.
Abstract
BACKGROUND: Outpatient clinics treating neuro-oncology patients are becoming more multidisciplinary. Utilization of all team members is critical for the holistic care of these complex patients. Specifically, the role of clinical pharmacist (CP) in the ambulatory clinic remains undefined and will likely evolve as more therapeutics are developed for CNS malignancies. We queried the Society for Neuro-Oncology (SNO) membership about the availability of a CP in their ambulatory setting and, if present, the role of that CP. METHODS: In an IRB-exempt study, we surveyed the SNO community and analyzed responses to queries about CPs in the ambulatory setting. RESULTS: Of the 65 SNO members who responded, 52 were clinical members. Of these 52 clinicians, the majority were physicians (88.5%, n = 46). Of these physicians, most were in academic practices (93.5%, n = 43). Over half of the 52 clinical respondents (51.9%, n = 27) reported that they saw ≥30 primary brain tumor patients per month, thus typifying busy clinics. Despite having busy clinics, only 12 (28.6%) of 42 providers with access to a CP reported that their CP was solely dedicated to neuro-oncology patients. For the respondents who had access to a CP, only ~two-thirds of those CPs had direct patient interaction. The top 3 roles of the CP included medication review, chemotherapy dosing/modifications, and practice guideline development; none of which involve direct patient interaction. CONCLUSIONS: We found that while our surveyed population of SNO clinical members have demanding outpatient practices, most do not have the support or expertise of dedicated neuro-oncology CPs.
BACKGROUND: Outpatient clinics treating neuro-oncology patients are becoming more multidisciplinary. Utilization of all team members is critical for the holistic care of these complex patients. Specifically, the role of clinical pharmacist (CP) in the ambulatory clinic remains undefined and will likely evolve as more therapeutics are developed for CNS malignancies. We queried the Society for Neuro-Oncology (SNO) membership about the availability of a CP in their ambulatory setting and, if present, the role of that CP. METHODS: In an IRB-exempt study, we surveyed the SNO community and analyzed responses to queries about CPs in the ambulatory setting. RESULTS: Of the 65 SNO members who responded, 52 were clinical members. Of these 52 clinicians, the majority were physicians (88.5%, n = 46). Of these physicians, most were in academic practices (93.5%, n = 43). Over half of the 52 clinical respondents (51.9%, n = 27) reported that they saw ≥30 primary brain tumor patients per month, thus typifying busy clinics. Despite having busy clinics, only 12 (28.6%) of 42 providers with access to a CP reported that their CP was solely dedicated to neuro-oncology patients. For the respondents who had access to a CP, only ~two-thirds of those CPs had direct patient interaction. The top 3 roles of the CP included medication review, chemotherapy dosing/modifications, and practice guideline development; none of which involve direct patient interaction. CONCLUSIONS: We found that while our surveyed population of SNO clinical members have demanding outpatient practices, most do not have the support or expertise of dedicated neuro-oncology CPs.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Eve M Segal; Jill Bates; Sara L Fleszar; Lisa M Holle; Julie Kennerly-Shah; Michelle Rockey; Kate D Jeffers Journal: J Oncol Pharm Pract Date: 2019-07-09 Impact factor: 1.809
Authors: Grant W Lee; Anupama D Mathur; Benjamin J Andrick; Erika Leese; Durga Zally; Na Tosha N Gatson Journal: J Oncol Pharm Pract Date: 2020-09-17 Impact factor: 1.809
Authors: Michael Weller; Martin van den Bent; Jörg C Tonn; Roger Stupp; Matthias Preusser; Elizabeth Cohen-Jonathan-Moyal; Roger Henriksson; Emilie Le Rhun; Carmen Balana; Olivier Chinot; Martin Bendszus; Jaap C Reijneveld; Frederick Dhermain; Pim French; Christine Marosi; Colin Watts; Ingela Oberg; Geoffrey Pilkington; Brigitta G Baumert; Martin J B Taphoorn; Monika Hegi; Manfred Westphal; Guido Reifenberger; Riccardo Soffietti; Wolfgang Wick Journal: Lancet Oncol Date: 2017-05-05 Impact factor: 41.316